Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial. (nature.com)

Authors: Besse B … Solomon BJ Journal: Nature Medicine Published: 2026-02-01 DOI: https://doi.org/10.1038/s41591-025-04079-7